iLoF and Bluepharma Team Up to Transform Drug Development with Optomics® AI Technology iLoF and Bluepharma have launched a strategic partnership to implement the AI-driven Optomics® platform, enhancing drug development and personalized medicine.

iLoF and Bluepharma Team Up to Transform Drug Development with Optomics® AI Technology #London #United_Kingdom #Optomics #iLoF #Bluepharma

Correcting for Genomic Inflation Leads to Loss of Power in Large‐Scale Genome‐Wide Association Study Meta‐Analysis Inflation in genome-wide association studies (GWAS) summary statistics represents a major challenge, for which correction methods have been developed. These include the genomic control (GC) method, w...

🚨New paper: doi.org/10.1002/gepi...

We show that correcting for genomic inflation in large GWAS studies might be throwing away important results - up to 40% of T2D loci!

#OPTOMICS is finding smarter ways to keep good data and still avoid bias. Better science, better health.🧬

OPTOMICS – Combining optoacoustic imaging phenotypes and multi-omics to advance diabetes healthcare

Finally, #OPTOMICS - a @horizoneu.bsky.social project is on Bsky!
We will inform you on latest advancements on #diabetes, #optoacoustic #imaging, #omics and how they all merge into a #digitaltwin to promote diabetes healthcare.

Take a look at our website!

optomics.munichimaging.eu